Merck & Co. Joins Forces with Roche for Promotion of Victrelis™

  title={Merck \& Co. Joins Forces with Roche for Promotion of Victrelis{\texttrademark}},
  author={Heather Cartwright},
  journal={Pharmadeals Review},
Merck & Co. and Roche, two rivals in the hepatitis C virus (HCV) market, have joined forces in a broad, non-exclusive collaboration to advance potential new treatment regimens for HCV infection. As a part of the deal, the two companies will promote Merck’s recently approved HCV drug Victrelis™ (boceprevir), initially in the US. The partnership will strengthen the drug’s position in the HCV drug market as it competes with Vertex Pharmaceuticals’ Incivek™ (telaprevir), which also gained US FDA… Expand
1 Citations

Topics from this paper

Proteases and protease inhibitors in infectious diseases